Springer Protocols: Abstract: 1. Exploiting Dendritic Cells for Active Immunotherapy of Cancer and Chronic Infection

1. Exploiting Dendritic Cells for Active Immunotherapy of Cancer and Chronic Infection

By: David O’Neill, Nina Bhardwaj³

Abstract

Full Text

Download PDF (151K)

Dendritic cells (DC) are important antigen-presenting cells (APC) that can prime naive T-cells and control lymphocyte-mediated adaptive immune responses with respect to magnitude, memory, and self-tolerance. Understanding the biology of these cells is central to the development of new generation immunotherapies for cancer and chronic infection. This chapter presents a brief overview of DC biology and the preparation and use of DC-based vaccines.

Affiliation(s): (3) NYU Cancer Institute Tumor Vaccine Center, New York University School of Medicine, New York, NY

Book Title: Adoptive Immunotherapy: Methods and Protocols

Series: Methods in Molecular Medicine | Volume: 109 | Pub. Date: Nov-30-2004 | Page Range: 1-18 | DOI: 10.1385/1-59259-862-5:001

Subject: Immunology

Key Words: Dendritic cells - antigen presentation - cancer vaccine - apoptotic cells - cyto-toxic T-lymphocytes

References

Download References

1.	Palucka, K. and Banchereau, J. (1999) Linking innate and adaptive immunity. Nat. Med. 5, 868–870.

2.	Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., and Schreiber, R. D. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991–998.

3.	Smyth, M. J., Godfrey, D. I., and Trapani, J.A. (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat. Immunol. 2, 293–299.

4.	Pardoll, D. (2003) Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807–839.

5.	Sant, A. and Yewdell, J. (2003) Antigen processing and recognition. Curr. Opin. Immunol. 15, 66–68.

6.	Banchereau, J., Briere, F., Caux, C., et al. (2000) Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767–811.

7.	Bhardwaj, N., Friedman, S. M., Cole, B. C., and Nisanian, A. J. (1992) Dendritic cells are potent antigen-presenting cells for microbial superantigens. J. Exp. Med. 175, 267–273.

8.	Fonteneau, J. F., Larsson, M., Somersan, S., et al. (2001) Generation of high quantities of viral and tumor-specific human CD4⁺and CD8⁺T-cell clones using peptide pulsed mature dendritic cells. J. Immunol. Methods. 258, 111–126.

9.	Steinman, R. M. and Pope, M. (2002) Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109, 1519–1526.

10.	Shortman, K. and Liu, Y. J. (2002) Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2, 151–161.

11.	MacDonald, K.P., Munster, D.J., Clark, G.J., Dzionek, A., Schmitz, J., and Hart, D.N. (2002) Characterization of human blood dendritic cell subsets. Blood 15, 15.

12.	Manz, M. G., Traver, D., Miyamoto, T., Weissman, I. L., and Akashi, K. (2001) Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood 97, 3333–3341.

13.	Wu, L., D’Amico, A., Hochrein, H., O’Keeffe, M., Shortman, K., and Lucas, K. (2001) Development of thymic and splenic dendritic cell populations from different hemopoietic precursors. Blood 98, 3376–3382.

14.	delHoyo, G. M., Martin, P., Vargas, H. H., Ruiz, S., Arias, C. F., and Ardavin, C. (2002) Characterization of a common precursor population for dendritic cells. Nature 415, 1043–1047.

15.	Medzhitov, R. (2001) Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135–145.

16.	Takeda, K., Kaisho, T., and Akira, A. (2003) Toll-like receptors. Annu. Rev. Immunol. 21, 335–376.

17.	Rafiq, K., Bergtold, A., and Clynes, R. (2002) Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 110, 71–79.

18.	Schuurhuis, D. H., Ioan-Facsinay, A., Nagelkerken, B., et al. (2002) Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8⁺CTL responses in vivo. J. Immunol. 168, 2240–2246.

19.	Figdor, C. G., van Kooyk, Y., and Adema, G. J. (2002) C-type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2, 77–84.

20.	Steinman, R. M., and Nussenzweig, M. C. (2002) Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99, 351–358.

21.	Steinman, R. M., Hawiger, D., and Nussenzweig, M. C. (2003) Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685–711.

22.	Hawiger, D., Inaba, K., Dorsett, Y., et al. (2001) Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769–779.

23.	Aderem, A. and Ulevitch, R. J. (2000) Toll-like receptors in the induction of the innate immune response. Nature 406, 782–787.

24.	Gallucci, S. and Matzinger, P. (2001) Danger signals: SOS to the immune system. Curr. Opin. Immunol. 13, 114–119.

25.	Pulendran, B., Palucka, K., and Banchereau, J. (2001) Sensing pathogens and tuning immune responses. Science 293, 253–256.

26.	Mellman, I. and Steinman, R. M. (2001) Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255–258.

27.	Lanzavecchia, A. and Sallusto, F. (2001) The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr. Opin. Immunol. 13, 291–289.

28.	Moody, D. B. and Porcelli, S. A. (2002) Intracellular pathways of CD1 antigen presentation. Nature Rev. Immunol. 3, 11–22.

29.	Porcelli, S. A. and Modlin, R. L. (1999) The CD1 system: antigen presenting molecules for T cell recognition of lipids and glycolipids. Annu. Rev. Immunol. 17, 297–329.

30.	Fujii, S., Shimizu, K., Kronenberg, M., and Steinman, R. M. (2002) Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat. Immunol. 3, 867–874.

31.	Kronenberg, M. and Gapin, L. (2002) The unconventional lifestyle of NKT cells. Nature Rev. Immunol. 2, 557–568.

32.	Bhardwaj, N. (2001) Processing and presentation of antigens by dendritic cells: implications for vaccines. Trends Mol. Med 7, 388–394.

33.	Heath, W. R. and Carbone, F. R. (1999) Cytotoxic T lymphocyte activation by cross-priming. Curr. Opin. Immunol. 11, 314–318.

34.	Albert, M. L., Sauter, B., and Bhardwaj, N. (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86–89.

35.	Heath, W. R. and Carbone, F. R. (2001) Cross-presentation in viral immunity and self-tolerance. Nat. Rev. Immunol. 1, 16–134.

36.	Kalergis, A. M. and Ravetch, J. V. (2002) Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J. Exp. Med. 195, 1653–1659.

37.	Savill, J., Dransfield, I., Gregory, C., and Haslett, C. (2002) A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2, 965–975.

38.	Stoll, S., Delon, J., Brotz, T. M., and Germain, R. N. (2002) Dynamic imaging of T cell-dendritic cell interactions in lymph nodes. Science 296, 1873–1876.

39.	Norbury, C. C., Malide, D., Gibbs, J. S., Bennink, J. R., and Yewdell, J. W. (2002) Visualizing priming of virus-specific CD8⁺T cells by infected dendritic cells in vivo. Nat. Immunol. 3, 265–271.

40.	Langenkamp, A., Casorati, G., Garavaglia, C., Dellabona, P., Lanzavecchia, A., and Sallusto, F. (2002) T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur. J. Immunol. 32, 2046–2054.

41.	Palucka, K. and Banchereau, J. (2002) How dendritic cells and microbes interact to elicit or subvert protective immune responses. Curr. Opin. Immunol. 14, 420–431.

42.	Boonstra, A., Asselin-Paturel, C., Gilliet, M.,’ et al. (2003) Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation. J. Exp. Med. 197,101–109.

43.	Lutz, M. and Schuler, G. (2002) Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 23, 445.

44.	Kaech, S. M. and Ahmed, R. (2003) CD8 T cells remember with a little help. Science 300, 263–265.

45.	Trinchieri, G. (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133–146.

46.	Balazs, M., Martin, F., Zhou, T., and Kearney, J. (2002) Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 17, 341–352.

47.	Jego, G., Palucka, A. K., Blanck, J. P., Chalouni, C., Pascual, V., and Banchereau, J. (2003) Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19, 225–234.

48.	Ferlazzo, G., Tsang, M. L., Moretta, L., Melioli, G., Steinman, R. M., and Munz, C. (2002) Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated nk cells. J. Exp. Med. 195, 343–351.

49.	Fujii, S., Shimizu, K., Kronenberg, M., and Steinman, R. M. (2002) Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat. Immunol. 3, 867–874.

50.	Berzofsky, J. A., Ahlers, J. D., and Belyakov, I. M. (2001) Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1, 209–219.

51.	Shankaran, V., Ikeda, H., Bruce, A. T., et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107–1111.

52.	Boon, T. and Old, L.J. (1997) Cancer tumor antigens. Curr. Opin. Immunol. 9, 681–683.

53.	Houghton, A. N., Gold, J. S., and Blachere, N. E. (2001) Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13, 134–140.

54.	Stevanovic, S. (2002) Identification of tumour-associated T-cell epitopes for vaccine development. Nat. Rev. Cancer 2, 514–520.

55.	Bendandi, M., Gocke, C. D., Kobrin, C. B., et al. (1999) Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5, 1171–1177.

56.	Livingston, P. (2001) The unfulfilled promise of melanoma vaccines. Clin. Cancer Res. 7, 1837–1838.

57.	Nestle, F. O. (2002) Vaccines and melanoma. Clin. Exp. Dermatol. 27, 597–601.

58.	Machiels, J. P., van Baren, N., and Marchand, M. (2002) Peptide-based cancer vaccines. Semin. Oncol. 29, 494–502.

59.	Marchand, M., van Baren, N., Weynants, P., et al. (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA^- A1. Int J. Cancer 80, 219–230.

60.	Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., et al. (1998) Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4, 321–327.

61.	Sabel, M. S., and Sondak, V. K. (2002) Tumor vaccines: a role in preventing recurrence in melanoma? Am. J. Clin. Dermatol. 3, 609–616.

62.	McClay, E. F. (2002) Adjuvant therapy for patients with high-risk malignant melanoma. Semin. Oncol. 29, 389–399.

63.	Banchereau, J., Schuler-Thurner, B., Palucka, A. K., and Schuler, G. (2001) Dendritic cells as vectors for therapy. Cell 106, 271–274.

64.	Brossart, P., Wirths, S., Brugger, W., and Kanz, L. (2001) Dendritic cells in cancer vaccines. Exp. Hematol. 29, 1247–1255.

65.	Fong, L. and Engleman, E. G. (2000) Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18, 245–273.

66.	Jefford, M., Maraskovsky, E., Cebon, J., and Davis, I. D. (2001) The use of dendritic cells in cancer therapy. Lancet Oncol. 2, 343–353.

67.	Nestle, F. O., Banchereau, J., and Hart, D. (2001) Dendritic cells: on the move from bench to bed side. Nat. Med. 7, 761–765.

68.	Ashley, D. M., Faiola, B., Nair, S., Hale, L. P., Bigner, D. D., and Gilboa, E. (1997) Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitu-mor immunity against central nervous system tumors. J. Exp. Med. 186, 1177–1182.

69.	Celluzzi, C. M. and Falo, L. D., Jr. (1998) Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 160, 3081–3085.

70.	Gilboa, E., Nair, S. K., and Lyerly, H. K. (1998) Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46, 82–87.

71.	Porgador, A., Snyder, D., and Gilboa, E. (1996) Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156, 2918–2926.

72.	Dhodapkar, M. V., Steinman, R. M., Sapp, M., et al. (1999) Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104,173–180.

73.	Dhodapkar, M. V., Krasovsky, J., Steinman, R. M., and Bhardwaj, N. (2000) Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J. Clin. Invest. 105, R9–R14.

74.	Nestle, F. O., Alijagic, S., Gilliet, M., et al. (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4, 328–332.

75.	Thurner, B., Haendle, I., Roder, C., et al. (1999) Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage iv melanoma. J. Exp. Med. 190, 1669–1678.

76.	Banchereau, J., Palucka, A. K., Dhodapkar, M., et al. (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61,6451–6458.

77.	Schuler-Thurner, B., Schultz, E. S., Berger, T. G., et al. (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195, 1279–1288.

78.	Kugler, A., Stuhler, G., Walden, P., et al. (2000) Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6, 332–336.

79.	Timmerman, J. M., Czerwinski, D. K., Davis, T. A., et al. (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99, 1517–1526.

80.	Hsu, F. J., Benike, C., Fagnoni, F., et al. (1996) Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2, 52–58.

81.	Heiser, A., Coleman, D., Dannull, J., et al. (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109,409–417.

82.	Fong, L., Brockstedt, D., Benike, C., Wu, L., and Engleman, E. G. (2001) Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166, 4254–4259.

83.	Fong, L., Brockstedt, D., Benike, C., et al. (2001) Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol. 167, 7150–7156.

84.	Small, E. J., Fratesi, P., Reese, D. M., et al. (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894–3903.

85.	Burch, P. A., Breen, J. K., Buckner, J. C., et al. (2000) Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6,2175–2182.

86.	Tjoa, B. A., Simmons, S. J., Bowes, V. A., et al. (1998) Evaluation of phase MI clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36, 39–44.

87.	Brossart, P., Wirths, S., Stuhler, G., Reichardt, V. L., Kanz, L., and Brugger, W. (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96, 3102–3108.

88.	Fong, L., Hou, Y., Rivas, A., et al. (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98, 8809–8814.

89.